ES2139077T3 - Medicamento contra el estres, la degeneracion y el envejecimiento y proceso para su fabricacion. - Google Patents
Medicamento contra el estres, la degeneracion y el envejecimiento y proceso para su fabricacion.Info
- Publication number
- ES2139077T3 ES2139077T3 ES94919023T ES94919023T ES2139077T3 ES 2139077 T3 ES2139077 T3 ES 2139077T3 ES 94919023 T ES94919023 T ES 94919023T ES 94919023 T ES94919023 T ES 94919023T ES 2139077 T3 ES2139077 T3 ES 2139077T3
- Authority
- ES
- Spain
- Prior art keywords
- stress
- drug
- enterosoluble
- vitamin
- aging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Addiction (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Materials For Medical Uses (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
LA INVENCION SE REFIERE A UNA NUEVA ESTRATEGIA FARMACOTERAPEUTICA, A UN FARMACO ANTIESTRES, ANTIDETERIORO Y ANTIENVEJECIMIENTO Y A UN PROCESO PARA SU FABRICACION. EL FARMACO TIENE UNA ACCION ETIOPATOGENICA Y HOMEOSTATICA, SE ENSAYO PRECLINICAMENTE Y VERIFICO CLINICAMENTE EN PATOLOGIAS GERIATRICAS, NEUROLOGICAS, PSIQUIATRICAS Y DEPENDIENTES DEL ESTRES. CON EL FARMACO SE CONSIGUE UNA COMPOSICION BIOLOGICA, NEUROMETABOLICA Y CELULOTROFICA, ELABORADA MEDIANTE LA ASOCIACION DE LOS SIGUIENTES PRINCIPIOS ACTIVOS: A) CONTRA EL ESTRES OXIDATIVO Y CATABOLICO: METIONINA CON AMINOETANOLFENOXIACETATOS Y/O AMINOETILFENOXIACETAMIDAS; B) CONTRA EL ESTRES ANABOLICO: CARBOXILATOS DE HIDROOXOPIRIMIDINA Y/O ACETAMIDAS DE OXOPIRROLIDINA CON POTASIO, ZINC Y LITIO; C) VASODILATADORA Y NORMOLIPIDEMICA: ALCOHOL Y/O ACIDO NICOTINICO, O SUS DERIVADOS, CON MAGNESIO Y YODO; D) ENERGOACTIVA Y E) ANTITOXICA: ASPARTATO; FRUCTOSA; VITAMINA B{SUB,1}; VITAMINA B{SUB,6}; FOSTATO Y SULFATO MONOACIDOS. EL PROCESO PARA LA FABRICACION DEL FARMACO ESTIPULA: A) PREPARACION FARMACEUTICA DE DOS TIPOS COMPLEMENTARIOS DE CAPSULAS O COMPRIMIDOS REVESTIDOS, GASTROSOLUBLES Y ENTEROSOLUBLES, DONDE LOS ULTIMOS TIENEN UN REVESTIMIENTO ENTERICO; B) LIBERACION PROLONGADA DEL VASODILATADOR DE LA UNIDAD ENTEROSOLUBLE.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/RO1994/000003 WO1995033486A1 (en) | 1994-06-02 | 1994-06-02 | Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof |
BR9408581A BR9408581A (pt) | 1994-06-02 | 1994-06-02 | Medicamento anti-tens o anti-incapacitação e anti-envelhecimento e processo para a sua produção |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2139077T3 true ES2139077T3 (es) | 2000-02-01 |
Family
ID=25664670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES94919023T Expired - Lifetime ES2139077T3 (es) | 1994-06-02 | 1994-06-02 | Medicamento contra el estres, la degeneracion y el envejecimiento y proceso para su fabricacion. |
Country Status (11)
Country | Link |
---|---|
US (1) | US6174890B1 (es) |
EP (1) | EP0804239B1 (es) |
JP (1) | JP3455544B2 (es) |
AT (1) | ATE184490T1 (es) |
AU (1) | AU694125B2 (es) |
BR (1) | BR9408581A (es) |
CA (1) | CA2191837C (es) |
DE (1) | DE69420746T2 (es) |
DK (1) | DK0804239T3 (es) |
ES (1) | ES2139077T3 (es) |
WO (1) | WO1995033486A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703127A (en) * | 1996-01-25 | 1997-12-30 | Pak; Kyoungsik | Composition, dosage unit, and method for treating stomach disorders |
GB2312621B (en) * | 1996-05-02 | 1998-03-11 | Pharma Nord Uk Limited | Anti-oxidant medicament |
US6337065B1 (en) * | 1998-12-01 | 2002-01-08 | University Of Kentucky Research Foundation | Method for enhancing protective cellular responses to genotoxic stress in skin |
US6726939B1 (en) | 2000-03-22 | 2004-04-27 | Kyoungsik Pak | Composition and method for reducing blood pressure, alleviating or eliminating angina pectoris and headaches, and enhancing skin and hair |
DE10018834A1 (de) * | 2000-04-15 | 2001-10-25 | Lohmann Therapie Syst Lts | Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung |
EA005383B1 (ru) * | 2001-12-28 | 2005-02-24 | Федеральное Государственное Унитарное Предприятие "Центр Экстремальной Медицины" | Способ фармакологической коррекции работоспособности человека в экстремальных ситуациях |
US20040001817A1 (en) * | 2002-05-14 | 2004-01-01 | Giampapa Vincent C. | Anti-aging nutritional supplement |
EP1550443A4 (en) * | 2002-09-18 | 2009-04-01 | Ajinomoto Kk | COMPOSITION AGAINST STRESS-BASED DISEASES |
ITRN20030021A1 (it) * | 2003-07-21 | 2005-01-22 | Ascor Chimici Srl | Composizione di materia comprendente particelle contenenti cloruro di colina da somministrare in forma ruminalmente protetta e post-ruminalmente efficace. |
US20050214388A1 (en) * | 2004-02-18 | 2005-09-29 | Gorham Thomas R | Multivitamin formulations containing controlled-release magnesium |
BRPI0511079A (pt) | 2004-05-11 | 2007-12-26 | Emotional Brain Bv | usos de uma combinação de um inibidor de pde5 e testosterona ou de um seu análogo, e de testosterona ou de um seu análogo, formulação farmacêutica, e, kit de partes |
ITMI20041820A1 (it) * | 2004-09-24 | 2004-12-24 | Ascor Chimici Srl | Composizione in micro-pellets a rilascio controllato di sostanze fisiologicamente attive, procedimento di preparazione e relativo impiego nel settore zootecnico. |
US20060153900A1 (en) * | 2005-01-13 | 2006-07-13 | Pins Joel J | Dietary supplement for treatment of lipid risk factors |
US20060252830A1 (en) * | 2005-05-06 | 2006-11-09 | Brandon Stephen F | Method for the treatment of magnesium and potassium deficiencies |
US20060252831A1 (en) * | 2005-05-06 | 2006-11-09 | Christopher Offen | Method for the treatment of magnesium and potassium deficiencies |
US7998500B2 (en) * | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US8263137B2 (en) * | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US8202546B2 (en) * | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7901710B2 (en) * | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
WO2007073006A1 (ja) * | 2005-12-22 | 2007-06-28 | Keio University | 細胞保護性を有するアミノ酸の増加誘導剤及び増加方法 |
EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
JP2008174512A (ja) * | 2007-01-22 | 2008-07-31 | Kracie Seiyaku Kk | 起床時疲労感改善用組成物 |
JP5788715B2 (ja) * | 2011-05-31 | 2015-10-07 | キリンホールディングス株式会社 | 酸素消費量及びエネルギー消費量の低減剤 |
BR112018071363A2 (pt) | 2016-04-19 | 2019-02-05 | Ferring Bv | composições farmacêuticas orais de nicotinamida |
WO2019161331A1 (en) * | 2018-02-19 | 2019-08-22 | Marshall Timothy M | Magnesium/lithium preparations for neuroprotection and neurotrophic benefits |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3493659A (en) | 1967-10-23 | 1970-02-03 | Hoffmann La Roche | Compositions and process for the production thereof |
-
1994
- 1994-06-02 CA CA002191837A patent/CA2191837C/en not_active Expired - Lifetime
- 1994-06-02 BR BR9408581A patent/BR9408581A/pt not_active Application Discontinuation
- 1994-06-02 EP EP94919023A patent/EP0804239B1/en not_active Expired - Lifetime
- 1994-06-02 DE DE69420746T patent/DE69420746T2/de not_active Expired - Lifetime
- 1994-06-02 DK DK94919023T patent/DK0804239T3/da active
- 1994-06-02 US US08/750,159 patent/US6174890B1/en not_active Expired - Lifetime
- 1994-06-02 WO PCT/RO1994/000003 patent/WO1995033486A1/en active IP Right Grant
- 1994-06-02 JP JP50071396A patent/JP3455544B2/ja not_active Expired - Fee Related
- 1994-06-02 ES ES94919023T patent/ES2139077T3/es not_active Expired - Lifetime
- 1994-06-02 AT AT94919023T patent/ATE184490T1/de active
- 1994-06-02 AU AU70104/94A patent/AU694125B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU694125B2 (en) | 1998-07-16 |
BR9408581A (pt) | 1997-08-26 |
ATE184490T1 (de) | 1999-10-15 |
JPH10500137A (ja) | 1998-01-06 |
WO1995033486A1 (en) | 1995-12-14 |
AU7010494A (en) | 1996-01-04 |
DE69420746D1 (de) | 1999-10-21 |
EP0804239A1 (en) | 1997-11-05 |
EP0804239B1 (en) | 1999-09-15 |
DE69420746T2 (de) | 2000-06-29 |
JP3455544B2 (ja) | 2003-10-14 |
DK0804239T3 (da) | 2000-04-03 |
US6174890B1 (en) | 2001-01-16 |
CA2191837A1 (en) | 1995-12-14 |
CA2191837C (en) | 2002-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2139077T3 (es) | Medicamento contra el estres, la degeneracion y el envejecimiento y proceso para su fabricacion. | |
AU2008216234B2 (en) | Improved stability in vitamin and mineral supplements | |
US7241456B2 (en) | Formulations for topical delivery of bioactive substances and methods for their use | |
CO6150127A2 (es) | Formulaciones de flibanserina y metodo para fabricarlas | |
US20070098786A1 (en) | Enteric valproic acid | |
KR102566670B1 (ko) | 피부 색소 침착 억제제 | |
DE3627423A1 (de) | Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung | |
WO2010032140A3 (en) | Pharmaceutical compositions and related methods of delivery | |
JP2023145496A (ja) | 神経細胞損傷の治療のためのアミノ酸組成物 | |
KR20190046895A (ko) | 신경퇴행성 질환의 치료를 위한 니코틴아미드 리보사이드 및 프테로스틸렌 조성물 및 방법 | |
US20100087546A1 (en) | Use of dimethyl sulfone (msm) to reduce homocysteine levels | |
EE03089B1 (et) | Ibuprofeeni sisaldav kihisev ravimpreparaat ja selle valmistamise meetod | |
ES2681343T3 (es) | Composiciones para la mejora de la función cerebral | |
CN109430833A (zh) | 一种用于提高生殖细胞活力的组合物及其应用 | |
IT1270239B (it) | Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo | |
WO2013079373A1 (de) | Kollagenhydrolysat und dessen verwendung | |
EP1390028A2 (en) | Use of lipoic acid for suppressing undesired haematological effects of chemotherapy and/or radiotherapy | |
WO2016073716A1 (en) | Methods of treating huntington's disease using cysteamine compositions | |
US20080317856A1 (en) | Compositions Containing A Capillary -Active System With Application -Relevant Differentiability, And The Use Thereof | |
PT2838529E (pt) | Composição que compreende ácido alfa-lipóico e honokiol para tratar neuropatias | |
JPS56110679A (en) | 55aminootetrazole derivative of retinoic acid* its manufacture and medicine containing it | |
EP2654743A1 (en) | Combination comprising d-apartic acid and l-arginine or salts thereof for the improvement of cognitive activities and memory in dementia such as dementia senile and alzheimer's disease | |
RU2726978C2 (ru) | Сочетание липоевой кислоты и таурина в качестве осмопротекторного агента | |
CA3041914C (en) | Anaerobic antioxidant composition | |
ES2290579T3 (es) | Suplemento nutricional que contiene acido alfa-lipoico y antocianosidos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 804239 Country of ref document: ES |